Loading
HC
H-Cyte, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Yurkowsky Michael, was filed 21 Jan 2020.
H-Cyte, Inc.: what insiders have been doing
H-Cyte, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Nothing new has been filed by managers of H-Cyte, Inc. in twelve months, the latest record being from 18 January 2024.
The full history, which starts in 2015, counts 40 purchases against 2 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
80
Thresholds
n/a
Buy Volume
€3M
40 ops. · all time
Sell Volume
€69,431
2 ops. · all time
Since the insiders bought
- -67.9%Entry US$170.00 · Close at T+365 US$54.50
- -31.6%Entry US$497.18 · Close at T+365 US$340.00
- -31.6%Entry US$497.18 · Close at T+365 US$340.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2022FY ended December 2022 · cache
US$0.00
Analyst consensus
Income statement
RevenueUS$453.5k
Gross profitUS$335.9k74% margin
EBITDA-US$9.9M-2187% margin
Net income-US$10.3M-2271.3% margin
Valuation
Beta467.44
Balance sheet & cash
Total debtUS$3.9M
Free Cash Flow-US$1.9M
Profitability & ownership
ROA-253.6%
% institutions0.0%
Last declaration on 18 January 2024
Declarations80 total
303,107 sharesCOMMON STOCKSEC:0001066152-24-000001:0
13,168 sharesCOMMON STOCKSEC:0001804351-24-000001:0
8,321,785 shares@ US$0.014100.0% of flowCOMMON STOCKSEC:0001193805-22-000535:0
41,608,884 shares@ US$0.014100.0% of flowCOMMON STOCKSEC:0001066152-22-000001:0
693,477 shares@ US$0.014100.0% of flowCOMMON STOCKSEC:0001066152-22-000002:0
21,500 shares@ US$0.16Common stockSEC:0001493152-21-015897:1
5,000 shares@ US$0.19Common stockSEC:0001493152-21-015897:2
5,000 shares@ US$0.20Common stockSEC:0001493152-21-015897:3
38,000 shares@ US$0.17100.0% of flowCommon stockSEC:0001493152-21-015897:0
15,518,111 shares@ US$0.4082COMMON STOCKSEC:0001804351-21-000001:0
4,368,278 shares@ US$0.39Common StockSEC:0001493152-20-011969:0
8,100 shares@ US$0.1294Common StockSEC:0001493152-20-000822:0
Canonical exit: 16 Apr 2020 (T+90)
5,000 shares@ US$0.135Common StockSEC:0001493152-20-000822:1
Canonical exit: 16 Apr 2020 (T+90)
10,000 shares@ US$0.145Common StockSEC:0001493152-20-000822:3
Canonical exit: 16 Apr 2020 (T+90)
1,900 shares@ US$0.13480.0% of flowCommon StockSEC:0001493152-20-000822:2
Canonical exit: 16 Apr 2020 (T+90)
27,500 shares@ US$0.14Common StockSEC:0001493152-19-019561:0
Canonical exit: 15 Mar 2020 (T+90)
7,500 shares@ US$0.11Common StockSEC:0001493152-19-019561:1
Canonical exit: 15 Mar 2020 (T+90)
4,225,634 shares0Common StockSEC:0001493152-19-014274:0
10,407 shares@ US$0.55Common StockSEC:0001493152-18-000488:0
4,093 shares@ US$0.5531.1% of flowCommon StockSEC:0001493152-18-000216:0
9,650 shares@ US$0.558Common StockSEC:0001493152-18-000050:0
350 shares@ US$0.52112.3% of flowCommon StockSEC:0001493152-18-000050:1
6,000 shares@ US$0.7020.5% of flowCommon StockSEC:0001493152-17-014767:0
Canonical exit: 15 Mar 2018 (T+90)
1,000 shares@ US$0.7020.5% of flowCommon StockSEC:0001493152-17-014766:0
Canonical exit: 15 Mar 2018 (T+90)
31,240 shares@ US$1.08Common StockSEC:0001493152-17-012292:1
25 of 80 declarations
About H-Cyte, Inc.
H-Cyte, Inc. is a United States-listed healthcare company with a micro-cap profile and a business model that remains in transition. Historically known as Medovex Corp, the company was renamed H-CYTE, Inc. and is now presented in SEC filings as a hybrid biopharmaceutical business focused on chronic respiratory and pulmonary disorders. SEC documents place its principal operating location in Tampa, Florida, United States, while the company’s clinic-related footprint has been associated with Lung Health Institute, later rebranded as Centers for Respiratory Health.
The company’s strategy is built around two complementary operating segments. First, its autologous infusion therapy business provides patient-specific treatments aimed at chronic lung conditions. Second, its biologics development division is intended to create and develop new therapies for underserved disease states. This combination gives H-CYTE a dual profile: part clinical services provider, part early-stage biotech developer. For investors, that means the equity should be viewed as a high-risk, high-uncertainty healthcare story rather than a mature operating platform.
Read moreShow less
From a competitive standpoint, H-CYTE operates in a crowded and highly regulated market where scale, capital access, reimbursement, and clinical validation matter enormously. It does not appear to compete on broad commercial breadth; instead, its positioning is based on specialization in respiratory care and on the possibility that its biologics pipeline could generate differentiated value over time. Relative to larger U.S. healthcare and biotech peers, H-CYTE’s strategic edge is narrower and more speculative, but potentially more asymmetric if execution improves.
Recent corporate developments highlighted in SEC filings include the company’s continued restructuring around respiratory health, the permanent closure of some clinic locations after the COVID period, and multiple financing transactions involving secured convertible notes in 2021. Those capital events underscore the company’s dependence on external funding and the potential for share dilution, which are important considerations for equity investors monitoring Form 4 insider activity and broader ownership dynamics.
The company’s website also indicates that its online investor resources are maintained separately and updated through its investor-relations portal. In short, H-Cyte, Inc. should be framed as a United States healthcare microcap, listed on the NYSE/NASDAQ ecosystem in the broad sense of U.S. public markets, with a business centered on respiratory care services and biologics development. Its investment case depends on clinical execution, funding discipline, and the ability to convert a niche healthcare thesis into sustainable commercial traction.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
